Pulmonx Corporation (NASDAQ:LUNG) Receives $7.66 Average Price Target from Analysts

Shares of Pulmonx Corporation (NASDAQ:LUNG) have been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $7.6643.

LUNG has been the topic of a number of research analyst reports. Piper Sandler downgraded shares of Pulmonx from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $9.00 to $2.50 in a research report on Thursday, July 31st. Stifel Nicolaus lowered their price objective on shares of Pulmonx from $16.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, July 31st. Wells Fargo & Company decreased their target price on shares of Pulmonx from $6.00 to $3.00 and set an “equal weight” rating for the company in a research report on Friday, August 1st. D. Boral Capital reissued a “buy” rating and issued a $16.00 target price on shares of Pulmonx in a research report on Monday, September 8th. Finally, Wall Street Zen raised shares of Pulmonx from a “sell” rating to a “hold” rating in a research report on Saturday, August 30th.

Hedge Funds Weigh In On Pulmonx

Several large investors have recently bought and sold shares of the stock. Bank of America Corp DE raised its stake in Pulmonx by 556.6% during the 2nd quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock valued at $1,246,000 after purchasing an additional 407,971 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Pulmonx by 3,328.7% in the 2nd quarter. Jane Street Group LLC now owns 88,631 shares of the company’s stock worth $230,000 after purchasing an additional 86,046 shares during the last quarter. Stonepine Capital Management LLC bought a new stake in shares of Pulmonx in the 2nd quarter worth about $378,000. Norges Bank bought a new stake in shares of Pulmonx in the 2nd quarter worth about $392,000. Finally, XTX Topco Ltd bought a new stake in shares of Pulmonx in the 2nd quarter worth about $149,000. 91.04% of the stock is currently owned by institutional investors and hedge funds.

Pulmonx Stock Performance

Shares of LUNG opened at $1.82 on Friday. The company’s 50 day moving average price is $2.00 and its 200 day moving average price is $3.56. Pulmonx has a 52 week low of $1.47 and a 52 week high of $9.37. The company has a market capitalization of $74.17 million, a PE ratio of -1.27 and a beta of 0.43. The company has a debt-to-equity ratio of 0.54, a quick ratio of 4.63 and a current ratio of 5.35.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings data on Wednesday, July 30th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02. Pulmonx had a negative net margin of 62.88% and a negative return on equity of 69.76%. The firm had revenue of $23.86 million for the quarter, compared to the consensus estimate of $23.46 million. Pulmonx has set its FY 2025 guidance at EPS. Research analysts expect that Pulmonx will post -1.55 EPS for the current fiscal year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.